Recently, a study showed that the plasma levels of a phosphorylated form of tau (p-tau217) increased over time in preclinical AD, e.g., cognitively unimpaired subjects with brain amyloid deposits, and prodromal stages of AD or MCI patients with brain amyloid deposits. Here, MAPT is linked to Alzheimer disease.